Navigation Links
Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR

April 10, 2013, New York, NY A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week's American Association of Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

"With new immunotherapy agents available to help patients with melanoma, researchers are developing prognostic biomarkers to determine who will benefit most to fully realize the potential of these treatments," explained Jedd D. Wolchok, PhD, MD, director of Ludwig's Collaborative Laboratory at Memorial Sloan-Kettering Cancer Center during his presentations at AACR. "By identifying targeted combinations of agents, the immune response can be improved in certain patients with melanoma, the most dangerous form of skin cancer."

Developments in immunotherapeutic treatment of ovarian cancer was highlighted in a "Meet the Expert" session with George Coukos, PhD, MD, director of the Ludwig Center for Cancer Research of the University of Lausanne. His presentation educated on current progress and future prospects in vaccine and adoptive T-cell therapy development, as well as immunomodulatory therapy tools available for immediate clinical testing. "Ovarian cancer remains a very important therapeutic challenge," commented Dr. Coukos. "With no drugs approved in two decades in the U.S. and no therapeutic targets emerging from deep sequencing analyses, immunotherapy could offer a promising new approach."

Dr. Geoffrey Greene's team at the Ludwig Center at the University of Chicago analyzed epigenetic regulators called microRNAs little pieces of ribonucleic acid that are present in all the cells in the body to better understand treatment challenges of metastasis and chemotherapy resistance in patients with triple negative breast cancer.

"Our research used a novel human tumor xenograft model to better understand the fundamental mechanisms of these tumors," said lead author Huiping Liu, Research Associate, Ben May Department and the Ludwig Center, University of Chicago. "We know that proteins turn genes on and off but so do microRNAs. Our team discovered a small yet influential microRNA known as 30c. When it is present in cells it inhibits metastasis and improves a patient's response to chemotherapy treatment. Our findings may provide a potential new treatment target for this difficult to treat cancer."

From Dr. Bing Ren's laboratory of gene regulation at the Ludwig Institute for Cancer Research in San Diego, post-doctoral fellow Gary Hon, PhD described how adult tissues retain an epigenetic memory of their past development. Further, Dr. Ren tutored conferees about research related to long-range control of gene expression in mammalian cells during an educational session.


Contact: Rachel Steinhardt
Ludwig Institute for Cancer Research

Related biology news :

1. Ludwig cancer researchers honored among first class of fellows in AACR Academy
2. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
3. High-strength material advancements at Wayne State University may lead to new, life-saving steel
4. P&G Beauty & Grooming to present advancements in skin aging & stress sweat at AAD Meeting
5. Stem cell finding could advance immunotherapy for lung cancer
6. Novel coronavirus well-adapted to humans, susceptible to immunotherapy
7. Epigenetics and epidemiology -- hip, hype and science
8. Not by DNA alone: How the epigenetics revolution is fostering new medicines
9. Sick from stress? Blame your mom… and epigenetics
10. Study finds epigenetics, not genetics, underlies homosexuality
11. Epigenetics shapes fate of brain vs. brawn castes in carpenter ants
Post Your Comments:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
Breaking Biology Technology: